Advertisement
The pooled prevalence of severe acute respiratory syndrome coronavirus 2 in asymptomatic children is 0.65 percent and is significantly associated with the incidence of COVID-19 in the general population

Prevalence of SARS-CoV-2 in Asymptomatic Children Identified

0
Prevalence of SARS-CoV-2 in asymptomatic children linked to incidence of COVID-19 in general population
Among adults hospitalized with laboratory-confirmed influenza

Heart Events Observed for ~12 Percent of Adults Hospitalized With Flu

0
Acute heart failure and acute ischemic heart disease are most common cardiovascular events
Internet searches indicative of acute anxiety peaked early in the COVID-19 pandemic

Web Searches Suggesting Acute Anxiety Spiked Early in COVID-19

0
Largest spike in acute anxiety queries recorded on March 28, 2020, with 52 percent more queries than expected
Return to hospital after discharge for inpatients with COVID-19 is infrequent

Return to Hospital Infrequent After COVID-19 Admission

0
COPD, hypertension, shorter length of stay, and no in-hospital anticoagulation tied to return
The use of blood plasma from COVID-19 survivors to treat patients hospitalized with the disease is still considered experimental

WHO: Plasma Therapy for COVID-19 Still Experimental

0
FDA 'emergency use authorization' does not mean plasma therapy has been proven safe and effective
The U.S. Food and Drug Administration on Sunday cleared the way for more hospitalized COVID-19 patients to be treated with the blood plasma of COVID-19 survivors.

FDA Approves Wider Use of Plasma as COVID-19 Treatment

0
President Donald Trump announced emergency approval as 'breakthrough' treatment during a news briefing Sunday
A school-located influenza vaccination intervention is associated with a reduction in the incidence of influenza hospitalization

School-Located Influenza Vaccine Intervention Beneficial

0
SLIV intervention linked to drop in incidence of influenza hospitalization in school-aged children, adults
Renin-angiotensin-aldosterone system inhibitors are beneficial for hypertensive patients with COVID-19

RAAS Inhibitors May Benefit HTN Patients With COVID-19

0
Risk for death, death/critical outcomes lower with use of RAAS inhibitors for hypertension
Patients with moderate COVID-19 receiving a five-day course of remdesivir have a statistically significant difference in clinical status compared with usual care

Clinical Impact of Remdesivir in Moderate COVID-19 Unclear

0
Significant difference seen in clinical status versus usual care for five-day, but not 10-day, course
About 1

Pop Concert Held to Learn More About COVID-19 Spread

0
Participants equipped with contact tracers to record movements, track the path of small respiratory particles